Patents by Inventor Thomas von Hirschheydt

Thomas von Hirschheydt has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11945839
    Abstract: The present invention relates to methods for separating multispecific CrossMab antibodies from light chain mispaired variants thereof in a solution comprising CrossMab bispecific antibodies and mispaired antibody variants thereof by hydrophobic interaction chromatography.
    Type: Grant
    Filed: December 20, 2018
    Date of Patent: April 2, 2024
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Thomas Von Hirschheydt, Petra Rueger, Birgit Weydanz, Hubert Hertenberger
  • Publication number: 20200369719
    Abstract: The present invention relates to methods for separating multispecific CrossMab antibodies from light chain mispaired variants thereof in a solution comprising CrossMab bispecific antibodies and mispaired antibody variants thereof by hydrophobic interaction chromatography.
    Type: Application
    Filed: December 20, 2018
    Publication date: November 26, 2020
    Inventors: Thomas Von Hirschheydt, Petra Rueger, Birgit Weydanz, Hubert Hertenberger
  • Patent number: 8058283
    Abstract: Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: January 29, 2007
    Date of Patent: November 15, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Konrad Honold, Jane Paul, Carl Roeschlaub, Wolfgang Schaefer, Stefan Scheiblich, Thomas Von Hirschheydt, Alan Whittle
  • Patent number: 7939532
    Abstract: Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: October 24, 2006
    Date of Patent: May 10, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Frederick Brookfield, Jonathan Gridley, Lothar Kling, Michael Prime, Ulrike Reiff, Wolfgang Von Der Saal, Thomas Von Hirschheydt
  • Patent number: 7879884
    Abstract: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: May 14, 2008
    Date of Patent: February 1, 2011
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Frederick Brookfield, Lothar Kling, Ulrike Reiff, Wolfgang Von der Saal, Thomas Von Hirschheydt
  • Publication number: 20100292247
    Abstract: Objects of the present invention are the compounds of formula I, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: October 24, 2007
    Publication date: November 18, 2010
    Applicant: F. HOFFMANN-LA ROCHE AG
    Inventors: Frederick Brookfield, Jonathan Gridley, Lothar Kling, Michael Prime, Ulrike Reiff, Wolfgang von der Saal, Thomas von Hirschheydt
  • Publication number: 20100256200
    Abstract: Objects of the present invention are the compounds of formula (I) their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: May 14, 2008
    Publication date: October 7, 2010
    Inventors: Frederick Brookfield, Lothar Kling, Ulrike Reiff, Wolfgang Von der Saal, Thomas Von Hirschheydt
  • Patent number: 7625896
    Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: November 8, 2006
    Date of Patent: December 1, 2009
    Assignee: Hoffman-La Roche Inc.
    Inventors: Lothar Kling, Ulrike Reiff, Manfred Schwaiger, Georg Tiefenthaler, Wolfgang von der Saal, Thomas von Hirschheydt
  • Publication number: 20090264485
    Abstract: Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: August 7, 2006
    Publication date: October 22, 2009
    Inventors: Hans-Willi Krell, Joerg Middeldorff, Ulrike Reiff, Thomas von Hirschheydt, Edgar Voss
  • Publication number: 20090093491
    Abstract: Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of the above-mentioned compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: September 28, 2006
    Publication date: April 9, 2009
    Inventors: Wolfgang Jenni, Thomas Von Hirschheydt, Edgar Voss
  • Publication number: 20090030020
    Abstract: Objects of the present invention are the compounds of formula I their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: January 29, 2007
    Publication date: January 29, 2009
    Inventors: Konrad Honold, Jane Paul, Carl Roeschlaub, Wolfgang Schaefer, Stefan Scheiblich, Thomas Von Hirschheydt, Alan Whittle
  • Patent number: 7429605
    Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: August 1, 2006
    Date of Patent: September 30, 2008
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Birgit Bossenmaier, Thomas Friess, Rolf Juchem, Lothar Kling, Irene Kolm, Hans-Willi Krell, Thomas von Hirschheydt, Edgar Voss
  • Publication number: 20080132699
    Abstract: The invention relates to a new process for the preparation of pyrazine derivatives of formula (I), which are useful as intermediates for the preparation of liquid crystalline media components or of pharmaceutically active substances.
    Type: Application
    Filed: March 31, 2005
    Publication date: June 5, 2008
    Inventors: Markus Ege, Wolfgang Jenni, Thomas Von Hirschheydt, Edgar Voss
  • Patent number: 7288557
    Abstract: The present invention relates to the compounds of formula I their pharmaceutically acceptable salts or esters, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: September 14, 2005
    Date of Patent: October 30, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Walter-Gunar Friebe, Ulrike Reiff, Thomas von Hirschheydt, Edgar Voss
  • Publication number: 20070123513
    Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of such compounds, pharmaceutical compositions containing them and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: November 8, 2006
    Publication date: May 31, 2007
    Inventors: Lothar Kling, Ulrike Reiff, Manfred Schwaiger, Georg Tiefenthaler, Wolfgang von der Saal, Thomas von Hirschheydt
  • Patent number: 7208506
    Abstract: The present invention relates to compounds of formula I wherein R1, R2 and R3 are defined herein, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: April 24, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Edward Boyd, Frederick Brookfield, Jonathan Gridley, Manfred Kubbies, Raymond Lau, Ulrike Reiff, Georg Tiefenthaler, Wolfgang von der Saal, Thomas von Hirschheydt, Timothy Woodcock
  • Publication number: 20070032530
    Abstract: The present invention relates to the compounds of formula I: their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above-mentioned compounds, pharmaceutical compositions containing such compounds and their manufacture, as well as the use of such compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: August 1, 2006
    Publication date: February 8, 2007
    Inventors: Birgit Bossenmaier, Thomas Friess, Rolf Juchem, Lothar Kling, Irene Kolm, Hans-Willi Krell, Thomas von Hirschheydt, Edgar Voss
  • Patent number: 7169781
    Abstract: Compounds of the general formula (I) are presented which arevaluable therapeutics for the treatment of cancer and cancer related diseases.
    Type: Grant
    Filed: October 12, 2004
    Date of Patent: January 30, 2007
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Konrad Honold, Stefan Scheiblich, Thomas von Hirschheydt, Edgar Voss
  • Publication number: 20070010564
    Abstract: The present invention relates to compounds of formula I wherein R1, R2 and R3 are defined herein, their pharmaceutically acceptable salts, enantiomeric forms, diastereoisomers and racemates, the preparation of the above compounds, medicaments containing them and their manufacture, as well as the use of the above compounds in the control or prevention of illnesses such as cancer.
    Type: Application
    Filed: June 29, 2006
    Publication date: January 11, 2007
    Inventors: Edward Boyd, Frederick Brookfield, Jonathan Gridley, Manfred Kubbies, Raymond Lau, Ulrike Reiff, Georg Tiefenthaler, Wolfgang von der Saal, Thomas von Hirschheydt, Timothy Woodcock
  • Patent number: 7144889
    Abstract: Compounds of the general formula (I) are presented and are valuable therapeutics for the treatment of cancer and cancer related diseases.
    Type: Grant
    Filed: October 6, 2004
    Date of Patent: December 5, 2006
    Assignee: Hoffman-La Roche Inc.
    Inventors: Thomas von Hirschheydt, Edgar Voss